Interaction Study of Zanubrutinib With Moderate & Strong CYP3A Inhibitors

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04551963
Study type	Interventional
Source	BeiGene
Contact
Status	Completed
Phase	Phase 1
Start date	November 15, 2020
Completion date	February 21, 2022

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02343120` - Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies	Phase 1/Phase 2
	Completed	`NCT02018861` - A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)	Phase 1/Phase 2
	Terminated	`NCT03701438` - Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
	Completed	`NCT02327078` - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)	Phase 1/Phase 2
	Recruiting	`NCT05683717` - A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies	Phase 1
	Completed	`NCT01775631` - Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma	Phase 1
	Active, not recruiting	`NCT01905813` - Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies	Phase 1
	Recruiting	`NCT05275504` - Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies	Phase 1
	Active, not recruiting	`NCT02457598` - Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies	Phase 1
	Recruiting	`NCT03050190` - A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies	Phase 1/Phase 2
	Recruiting	`NCT03125577` - Combination CAR-T Cell Therapy Targeting Hematological Malignancies	Phase 1/Phase 2
	Recruiting	`NCT04170283` - Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies	Phase 3
	Recruiting	`NCT04509700` - Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)	Phase 2
	Not yet recruiting	`NCT03642496` - Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies	Early Phase 1
	Completed	`NCT00983619` - A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies	Phase 1/Phase 2